J&J Strengthens Diabetes Pipeline With Two Deals
A late-stage deal for a type 1 treatment and an early-stage deal for a series of type 2 compounds help J&J's move into diabetes, where it has traditionally been strong in blood glucose monitoring.
A late-stage deal for a type 1 treatment and an early-stage deal for a series of type 2 compounds help J&J's move into diabetes, where it has traditionally been strong in blood glucose monitoring.